KAZIA THERAPEUTICS LTD (KZIA) - Dilution Analysis

POS AM filing: This POS AM filing relates to the offering of ADSs representing ordinary shares by selling shareholders.

POS AM filing: This prospectus relates to the resale of American Depositary Shares (ADSs) representing ordinary shares issuable upon exercise of warrants by the selling shareholder.

F-1 filing: This F-1 filing describes an offering of American Depositary Shares (ADSs) by selling shareholders, representing ordinary shares, including ADSs issuable upon the exercise of pre-funded and placement agent warrants.

20-F filing | 809.4M shares outstanding

F-1 filing: This F-1 filing pertains to the resale of American Depositary Shares (ADSs) representing ordinary shares by selling shareholders.

F-1 filing: The filing is an F-1 registration statement for the resale of ADSs representing ordinary shares issuable upon the exercise of warrants by selling shareholders.

POS AM filing: This POS AM filing covers the resale of ADSs by a selling shareholder and the potential sale of ADSs to Alumni Capital under a purchase agreement.

POS AM filing: This POS AM filing relates to the offering of ADSs (American Depositary Shares) by selling shareholders. Each ADS represents one hundred ordinary shares. The selling shareholders may sell or transfer the ADSs from time to time on the Nasdaq Capital Market or in private transactions. The company will not receive any proceeds from the sale of these ADSs, but may receive proceeds from the exercise of warrants.

20-F filing | 332.9M shares outstanding

F-3 filing: The company is filing an F-3 form to register the offering of American Depositary Shares (ADSs) representing ordinary shares, with a total proposed amount of $100,000,000, and also for at the market offerings up to $10,000,000.

F-1 filing: This F-1 filing discusses the resale of ADSs representing ordinary shares by a selling shareholder, issued or issuable upon exercise of a new warrant, with the company not receiving proceeds from the sale but potentially receiving proceeds from the exercise of the warrant for general corporate purposes.

F-1 filing: This F-1 filing outlines a proposed offering for the resale of up to 88,500,000 ADSs representing 885,000,000 Ordinary Shares by a Selling Shareholder and also the possible sale of ADSs to Alumni Capital for up to $15.75 million.

F-1 filing: This F-1 filing relates to the resale by selling shareholders of up to 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares of Kazia Therapeutics Limited.

F-3 filing: This F-3 filing relates to the resale from time to time of 591,697 American Depositary Shares representing 5,916,970 Ordinary Shares of Kazia Therapeutics Limited by the selling shareholder.

20-F filing | 228.0M shares outstanding

20-F filing | 138.8M shares outstanding

20-F filing | 132.0M shares outstanding

F-3 filing: This is an F-3 filing for a shelf offering of American Depositary Shares representing ordinary shares and warrants with a total aggregate value of up to $100,000,000.

20-F filing | 94.6M shares outstanding